Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue.

Manfredi S, Pagenault M, de Lajarte-Thirouard AS, Bretagne JF.

Eur J Gastroenterol Hepatol. 2007 Nov;19(11):1021-5.

PMID:
18049175
2.

Presentation, treatment, and outcome of type 1 gastric carcinoid tumors.

Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB.

J Surg Oncol. 2006 Apr 1;93(5):368-72.

PMID:
16550587
3.

Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.

Jianu CS, Fossmark R, Syversen U, Hauso Ø, Fykse V, Waldum HL.

Scand J Gastroenterol. 2011 Apr;46(4):456-63. doi: 10.3109/00365521.2010.539255. Epub 2010 Dec 7.

PMID:
21133821
4.

Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.

Khuroo MS, Khuroo MS, Khuroo NS.

J Gastroenterol Hepatol. 2010 Mar;25(3):548-54. doi: 10.1111/j.1440-1746.2009.06131.x. Epub 2010 Jan 14.

PMID:
20074162
5.

Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.

Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P.

Endocr Relat Cancer. 2008 Mar;15(1):337-42. doi: 10.1677/ERC-07-0251.

6.
7.
8.

Medical treatment of neuroendocrine gut and pancreatic tumors.

Oberg K, Eriksson B.

Acta Oncol. 1989;28(3):425-31. Review.

PMID:
2472826
9.

[Carcinoid tumors].

Tóth M, Prónai L, Németh AM, Tulassay Z.

Orv Hetil. 2002 May 12;143(19 Suppl):1087-92. Review. Hungarian.

PMID:
12063867
10.

Somatostatin analogue phase I trials in neuroendocrine neoplasms.

Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Oates J.

Acta Oncol. 1993;32(2):217-23.

PMID:
7686764
11.

Gastric carcinoid type I tumour: new diagnostic and therapeutic method.

Prommegger R, Bale R, Ensinger C, Sauper T, Profanter C, Knoflach M, Moncayo R.

Eur J Gastroenterol Hepatol. 2003 Jun;15(6):705-7. No abstract available.

PMID:
12840685
12.

Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis.

Roti E, Minelli R, Gardini E, Salvi M, Bianconi L, Balducci L, Manfredi A, Braverman LE.

J Endocrinol Invest. 1990 Jan;13(1):69-72.

PMID:
2319110
13.

Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.

Arnold R, Frank M, Kajdan U.

Digestion. 1994;55 Suppl 3:107-13. Review.

PMID:
7698532
14.

Gastric carcinoid.

Mulkeen A, Cha C.

Curr Opin Oncol. 2005 Jan;17(1):1-6. Review.

PMID:
15608504
15.
16.

En-bloc resection of multiple type 1 gastric carcinoid tumors by endoscopic multi-band mucosectomy.

Hopper AD, Bourke MJ, Hourigan LF, Tran K, Moss A, Swan MP.

J Gastroenterol Hepatol. 2009 Sep;24(9):1516-21. doi: 10.1111/j.1440-1746.2009.05909.x.

PMID:
19743997
17.

Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.

Oberg K, Norheim I, Theodorsson E.

Acta Oncol. 1991;30(4):503-7.

PMID:
1854508
19.

[Management of digestive system carcinoid tumors and carcinoid syndrome].

Mondragón Sánchez RJ, Castillero Pinilla C, Saldívar Moreno C, Oñate Ocaña LF, Ruiz Molina JM, Aiello Crocifoglio V.

Rev Gastroenterol Mex. 1998 Oct-Dec;63(4):204-10. Spanish.

PMID:
10319670
20.

Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.

Deguchi H, Deguchi K, Tsukada T, Murashima S, Iwasaki E, Tsuda M, Kobayashi T, Shirakawa S.

Intern Med. 1994 Feb;33(2):100-2.

Supplemental Content

Support Center